SELLAS Life Sciences posts $10.1M Q3 loss as pivotal leukemia trial results approach

SELLAS' financial loss underscores the high stakes of its leukemia trials, potentially impacting future funding and strategic directions.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to Crypto Briefing.